Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Linvoseltamab |
| Trade Name | Lynozyfic |
| Synonyms | REGN5458|REGN-5458|REGN 5458|Anti-BCMA/CD3 BiTE|linvoseltamab-gcpt |
| Drug Descriptions |
Lynozyfic (linvoseltamab) is a bispecific antibody that binds to TNFRSF17 (BCMA) and CD3 with potential antitumor activity (Blood (2019) 134 (Supplement_1): 3176). Lynozyfic (linvoseltamab) is FDA-approved for use in patients with previously-treated relapsed or refractory multiple myeloma (FDA.gov). |
| DrugClasses | CD3 Antibody 119 TNFRSF17 Antibody 22 |
| CAS Registry Number | NA |
| NCIT ID | C158504 |